iGlarLixi: A new once-daily fixed-ratio combination of basal insulin glargine and lixisenatide for the management of type 2 diabetes
Diabetes Spectrum May 25, 2018
Hinnen D, et al. - In this review, researchers analyzed clinical evidence regarding dosing and administration of iGlarLixi, a titratable fixed-ratio combination of insulin glargine and the glucagon-like peptide (GLP)-1 receptor agonist lixisenatide that effectively lowers both fasting and postprandial glucose levels. In patients with type 2 diabetes requiring additional glycemic control, findings showed the efficacy as well as good tolerability of iGlarLixi as a treatment option with comparable or improved safety outcomes than its separate components. Adherence may be improved with iGlarLixi, attributed to its simple regimen and low rate of adverse effects. Improved adherence may lead to improved therapeutic outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries